Denali Therapeutics Inc.
NEWS
Shares of Denali Therapeutics are up more than 10 percent in premarket trading after the company announced it has inked a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases.
Denali Therapeutics stock climbed 11 percent after the release of positive data from its Phase I clinical trial of DNL201 in Parkinson’s disease.
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease. Multiple drugs have failed in late-stage trials and some companies, such as Pfizer, have largely given up on the space.
Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.
A look at whether big money and big deals will be in store for 2018.
Will this new buy be enough for Celgene investors?
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
JOBS
IN THE PRESS